Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
Standard
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites. / Bokemeyer, Carsten.
In: EXPERT OPIN BIOL TH, Vol. 10, No. 8, 8, 2010, p. 1259-1269.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
AU - Bokemeyer, Carsten
PY - 2010
Y1 - 2010
N2 - Malignant ascites is a sign of advanced tumour growth and is associated with significant morbidity and a poor prognosis with a median survival time of a few months. Paracentesis is a recommended treatment for malignant ascites, but can cause complications, for example infections, injury of abdominal organs, persistent leakage of ascites, and haematoma/haemorrhage. The European Medicines Agency (EMA) approved the use of a trifunctional bispecific antibody, catumaxomab (Removab), for the intraperitoneal (i.p.) treatment of malignant ascites in April 2009.
AB - Malignant ascites is a sign of advanced tumour growth and is associated with significant morbidity and a poor prognosis with a median survival time of a few months. Paracentesis is a recommended treatment for malignant ascites, but can cause complications, for example infections, injury of abdominal organs, persistent leakage of ascites, and haematoma/haemorrhage. The European Medicines Agency (EMA) approved the use of a trifunctional bispecific antibody, catumaxomab (Removab), for the intraperitoneal (i.p.) treatment of malignant ascites in April 2009.
M3 - SCORING: Zeitschriftenaufsatz
VL - 10
SP - 1259
EP - 1269
JO - EXPERT OPIN BIOL TH
JF - EXPERT OPIN BIOL TH
SN - 1471-2598
IS - 8
M1 - 8
ER -
